Peer Review History

Original SubmissionMarch 18, 2024
Decision Letter - Daryl Higgins, Editor

PONE-D-24-08327Australian Communities That Care (CTC) intervention: Benefit-cost analysis of a community-based youth alcohol prevention initiativePLOS ONE

Dear Dr. Abimanyi-Ochom,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 26 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Daryl Higgins, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Thank you for stating the following financial disclosure: 

 [Bosco Rowland, John W Toumbourou and Rob Carter received funding from The National Health and Medical Research Council (APP1087781) and Australian Research Council (LP100200755).].  

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

[Bosco Rowland, John W Toumbourou and Rob Carter received funding from the National Health and Medical Research Council (APP1087781) and Australian Research Council (LP100200755).]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

  [Bosco Rowland, John W Toumbourou and Rob Carter received funding from The National Health and Medical Research Council (APP1087781) and Australian Research Council (LP100200755).].  

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Competing Interests section: 

[The following authors served in the not-for-profit company Communities That Care Ltd that was evaluated in this paper:

Rowland (current Chief Executive Officer, CEO) and Toumbourou (Director and ex-CEO). Conflict of interest management strategies were approved by their Deakin University employer.]. 

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. 

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

5. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. In the online submission form, you indicated that [The benefit-cost model data includes multiple excel files with spreadsheets and are stored in the University secured data storage. Data can be provided on request from authors.]. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

Additional Editor Comments:

Despite a significant number of attempts, I haven't been able to secure 2 reviews. However, I agree with the review comments that I have received, and so as to not hold up the process any further, I am making my recommendation on the basis of the review that I have received.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Australian Communities that Care Intervention: B-C analysis of a community-based youth alcohol prevention initiative.

As the authors note adolescent and youth alcohol drinking is a public health concern. And evidence on what works and is cost-effective is valuable.

However despite being nicely written the underlying logic is not convincing, and in particular whether the trial outcomes that inform this B-C analysis are suitable to answer the research question.

A Cost - Benefit analysis relies entirely on the interpretation of reported outcomes, in this case of a CTC intervention in 5 localities. As such it would be useful to restate the key outcomes being draw on and what they mean. As I understand the outcomes from the Toumbourou et al 2019 paper as reported, the key question related to alcohol assumption was about number of drinks a year 8 student had even consumed - defined as more than a few sips of an alcoholic beverage ever – dichotomised into ever vs never. It is not self-evident that this would be a useful descriptor of alcohol consumption from which to model impacts of alcohol consumption on ED attendance, criminal behaviour etc – which might rather have been related more to intoxication. If this is a mis-interpretation please describe more clearly the trial data on which the modelling is based. But if correct, greater attention as to why this outcome is considered sound for assessing the impacts of alcohol needs to be made. The B-C analysis rests on this.

In particular, given the vast majority of benefits were from a modelled crime reduction, evidence to support the plausibility of the assumptions here are crucial. For example does a PAF for alcohol related youth crime, necessarily translate into what would be avoided if alcohol consumption was reduced – is the PAF is based on an association or a causal link. Further in terms of evidence from this study, perhaps explain why a 1%pa reduced likely of ever having a drink in year 8 in a community is linked to the number of adolescents who might get intoxicated and perhaps more likely to participate in crime. There seems to be a few logic steps missing.

The survey on which the CTC evaluation was based did include questions on anti-social behaviour including involvement in criminal activity – but it appears this wasn’t used in the C-B analysis. It is not clear why not?

Finally, ensuring the intervention is fully costed is clearly important. I could not locate the details on how the costing was done. Specifically what was the source of the costing data, do costs reflect a full cost,for example if office space were made available at below-market rate – how was that treated? It is unclear what is covered under salary costs – does it include wage on-costs and salary overheads (eg for HR, financial services, IT other agency costs).

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

The response to the specific reviewer and editor comments have been included in the response to reviewers document.

Attachments
Attachment
Submitted filename: Reviewer comments - 26072024.docx
Decision Letter - Daryl Higgins, Editor

PONE-D-24-08327R1Australian Communities That Care (CTC) intervention: Benefit-cost analysis of a community-based youth alcohol prevention initiativePLOS ONE

Dear Dr. Abimanyi-Ochom,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 15 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Daryl Higgins, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The key areas for improvement are suggested below, I have attached a more detailed feedback in the track-changed Word document.

1. Assumptions: Oversimplification of the relationship between alcohol use and health outcomes (e.g., proportional reductions in adverse events). The assumption of confounding variables not being controlled needs to be addressed (e.g., socioeconomic status, mental health conditions).

2. Methodology: Limiting analysis to the first cycle of the intervention may underestimate long-term costs. Clarification on long-term benefits in the discussion is required. Confounding factors like varying levels of alcohol reduction are not accounted for (e.g., small vs large reductions in consumption).

3.Definitions: Expanding on definitions (e.g., examples of crimes attributed to alcohol use) to aid non-expert readers.

4.Future Recommendations: Suggestion to include a cost-effectiveness analysis in future research. Highlighting the limitations of self-reported data (e.g., potential response bias).

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Dhatsayini Rattambige

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Comments_DR.docx
Revision 2

Dear Reviewers,

Thank you for the opportunity to revise our manuscript. We appreciate the valuable feedback provided. Please see attached document "Response to Reviewer Comments" for our response to all the reviewer comments (also copied below).

Response to reviewers

#

Reviewer comment

Response

1

While these estimates are drawn from established sources, the analysis assumes that any reduction in alcohol use will directly lead to proportional reductions in adverse events. This may oversimplify the relationship between alcohol use and health outcomes, as reductions in use do not always translate linearly to avoided event - would you be able to highlight this in the discussion/limitation section?

We appreciate this comment. As suggested, this limitation was included in the discussion section.

The change can be found on Page 23, line 369- 371

The model assumes that a reduction in alcohol consumption will lead to proportional decreases in adverse events. However, this relationship is not always linear, and reductions in alcohol use do not consistently result in equivalent decreases in adverse events.

2

The analysis only considers the costs from the first cycle of the intervention, despite acknowledging that there were multiple cycles during the intervention period limiting the analysis to the first cycle, the total long-term costs of maintaining or repeating the intervention are not fully captured. It may potentially underestimate the true costs of scaling or sustaining the intervention over time - however in the discussion long-term benefits are discussed in the discussion, could you clarify this?

Thank you for this comment. To clarify this, three of the four communities had one cycle; therefore, the cost was only associated with one cycle for comparability across the four communities. However, future CTCs can consider all the cycles. The evidence from this study shows that the cost per youth/year reduces over future cycles, highlighting possible economies of scale as the number of CTCs cycles increase.

We have revised this on Page 9, line 176 -179

Only the first cycle was considered when there were multiple cycles during the intervention period for comparability across the four communities (see S2 Example anonymised Australian CTC community cost template) (three of the four communities had only one cycle).

Also revised on page 21, Line 317-318

(displaying probable economies of scale as the number of CTCs cycles increase).

3

how was this assumption established? were any other variables controlled? - If you have the data to control any confounding variables, perhaps add it to the analysis, if not it may need to be acknowledged in the discussions

We appreciate this comment. This assumption was derived from the established evidence between risky alcohol consumption and alcohol related adverse events based on the NHMRC. Australian guidelines to reduce health risks from drinking alcohol. Canberra, ACT: National Health and Medical Research Council; 2009

We have specified this on page 9, line 184 to 187

This assumption was derived from the established evidence between risky alcohol consumption and alcohol related adverse events based on the National Health and Medical Research Council (NHMRC) guidelines. The reduction in alcohol-related adverse events were estimated for risky alcohol consumption based on the NHMRC guidelines 31.

4

Would it be beneficial to expand these definitions by providing examples of what these measure? for example I would be interested to understand what crimes were measured as being attributed to alcohol use

Thank you for this suggestion. All the adverse events are alcohol related, including crime, using data from turning point which collects data on alcohol related adverse events. The text was updated to make this clear on pages 9-10, line 195-198.

See response to #3 above, also line 184 to 187

5

Perhaps an example could help non-expert readers follow? (e.g., a reduction in alcohol use might simultaneously reduce e.g: crime and hospital admissions, both of which could be considered separately

We appreciate this comment. We’ve included an example as below:

Page 10, line 201 to 204 (e.g., when the same patient utilises the ambulance, ED, and in-hospital care for a hospital admission, these events were considered as three separate patients and then the join effect was applied to attribute those events to that one patient)

6

this approach may be limited in its ability to handle complex variables and interactions. not sure if this standard in the industry- please clarify

other confounding factors are discounted in my opinion (e.g., socioeconomic status, mental health conditions). Also, the model does not account for varying levels of alcohol consumption reduction. For example, small reductions in alcohol consumption may not result in a proportional decrease in adverse events, especially for those already engaging in harmful drinking patterns. Whereas, large reductions in consumption may have a more substantial impact, but the model does not differentiate between these effects - if you have the data for this, please include it in the analysis, if not please address this in the discussion

We understand your concern regarding confounding. In economic evaluation and modelling, it is normal practice to use Excel or Triage for health economic modelling, without controlling for confounders.

In this case, we’ve used the reduction in alcohol consumption to model averted alcohol related adverse events for risky alcohol consumers (by age group, gender and community). We acknowledge that the reduction may not be proportionate within this group and have indicated this as a limitation (please see response # 1).

7

why? This could lead to an incomplete assessment of the intervention's full value, as improvements in mental health, stress reduction, or quality of life are often central to public health initiatives and in the overall prevention of relapses in any alcohol related harms: Social Determinants of Health and Alcohol Use:

Galea, S., Nandi, A., & Vlahov, D. (2004). The social epidemiology of substance use. Epidemiologic Reviews, 26(1), 36-52.

If you have the data for this, please consider including it in the analysis, if not please address this limitation in the discussion

We agree that this leads to an incomplete assessment. However, the CTC study didn’t collect quality of life data. We therefore applied a limited-social perspective. The method section has been updated to indicate this.

We say limited-social perspective (on page 5) because it does not account for quality of life and wellbeing.

This has also been considered in the limitation section (line 396).

8

I am wondering if the cost per event could vary by region? - please add a footnote to the table acknowledging this

Thank you for this query. Cost per event was comparable and not different across regions.

9

could this capture complex interactions between multiple variables. For example, changes in youth exposure to the intervention may not have the same proportional impact on different outcomes ?

We do not agree that bootstrapping in this study would adequately capture complex interactions between multiple variables. Typically, bootstrapping captures synchronous variations among all the model inputs.

10

I may not have understood this, but how was this conclusion derived if the BC analysis was only applied during the intervention period

Not clear how the long-term impact has been measured in this study

Yes, we agree – there is some misunderstanding:

We were exploring the existing evidence in the literature in the discussion. We compared our results with other studies which included both short-term and long-term impact. We have only considered short-term impact in this study, as mentioned in the method and discussion.

11

Didn’t the primary analysis only consider the 1st cycle? or did the analysis also include other cycles but did not include in the ms?

We appreciate this comment. In our analysis, we used the first cycle since all communities had the one cycle for comparability across the four communities. We acknowledge that communities can have more than one cycle and discover economies of scale, and therefore discussion about it was noteworthy.

In the method section, we have now highlighted that ¾ of the communities had only one cycle (hence, only one had two cycles).

Please see the response to comment #2.

12

I think some more limitations should be included both the Toumbourou study and the BCA rely on self-reported data to estimate alcohol use, which could lead to response bias. Self-reported measures may under-report actual consumption levels, leading to underestimated benefits of the intervention​

Thank for highlighting this. We have included this as a limitation as suggested.

This change can be found on page 23, Line 362-365

Self-reported data on alcohol use is a limitation due to the potential for response bias. Since adolescents are generally not expected to consume alcohol, these self-reported measures may under-report actual consumption levels, thereby obscuring the true benefits of the intervention.

13

I also wonder if the inclusion of a Cost effectiveness analysis might be suggested here? perhaps as future recommendation to avoid complicating this paper? this could give a bigger picture on the overall effectiveness of CTA when compared to alternative programs without necessarily quantifying it in monetary value…

IF you do have data to do a cost effectiveness analysis, please consider adding this, if not, as suggested above, consider adding to recommendation

Thank you for this suggestion. We included this in the conclusion as below (….incorporate more robust experimental designs,…). This has been modified as follows.

We have revised this on Page 24 to 25, line 407-411

Future research should examine the economic benefits of prevented youth tobacco and cannabis use as well as antisocial behavior as demonstrated in the Australian CTC Trial 6. Additionally, it should utilise more robust experimental designs, including randomised control trials, and consider average absolute reductions that accounts for age, gender, length of intervention period, and long-term benefits for cost effectiveness analysis.

We believe that the revisions have strengthened our manuscript, and we hope it meets your expectations. Thank you once again for your insightful comments.

Sincerely,

Julie Abimanyi-Ochom

Deakin Health Economics, Deakin University

Attachments
Attachment
Submitted filename: Response to reviewer comments.docx
Decision Letter - Daryl Higgins, Editor

Australian Communities That Care (CTC) intervention: Benefit-cost analysis of a community-based youth alcohol prevention initiative

PONE-D-24-08327R2

Dear Dr. Abimanyi-Ochom,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Daryl Higgins, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for addressing all the comments and for providing more clarity. There are no further comments from my end.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Dhatsayini Rattambige

**********

Formally Accepted
Acceptance Letter - Daryl Higgins, Editor

PONE-D-24-08327R2

PLOS ONE

Dear Dr. Abimanyi-Ochom,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Daryl Higgins

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .